Repligen Corp (RGEN) is a globally recognized bioprocessing focused life sciences company. With its headquarters in Waltham, Massachusetts, USA, Repligen has evolved over the years from being purely a life sciences product manufacturer to a world leader in bioprocessing technologies and solutions.
Founded in 1981, Repligen's main focus is on producing innovative solutions for biological drug discovery and production. The company offers a wide range of innovative, high-quality products and services aimed at improving the capacity and cost-effectiveness of the biopharmaceutical production process. These products include pre-packed columns and chromatography resins, filtration systems, protein A ligands, growth factors, and bioreactors.
Repligen's leading proprietary product, Protein A, is a key reagent used in the production of monoclonal antibody-based therapeutics. This product has been an essential component in the manufacturing of these therapies for a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases.
The company remains committed to expanding its product catalog to serve a growing customer base that includes some of the world's top biopharmaceutical and life sciences companies. This focus on customer satisfaction and innovation has allowed Repligen to secure a strong position in the market, with operations extending across North America, Europe, and Asia.
Since 2011, Repligen has been continuously growing via strategic acquisitions. Companies like Novozymes Biopharma, Atoll, Refine Technologies, and Spectrum Laboratories have been integrated into the Repligen network enhancing its product line and geographical footprint.
Part of the company's strength lies in its ambitious Research and Development initiatives. Repligen is constantly innovating and seeking opportunities to expand and improve its product line and the services it offers.
Repligen's progress and success in the bioprocessing industry are reflected in its financial performance. The company has shown strong growth and consistently reported favorable financial results over several successive quarters.
Now with over four decades of experience, Repligen continues to be driven by a combination of scientific curiosity, manufacturing expertise, and a desire to make a lasting impact on human health. Its commitment to delivering high-quality bioprocessing products and solutions has made it a trusted partner to the biopharmaceutical industry worldwide.